Invention Grant
US07902229B2 Anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
失效
邻氨基苯甲酰胺吡啶脲作为血管内皮生长因子（VEGF）受体激酶抑制剂
- Patent Title: Anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
- Patent Title (中): 邻氨基苯甲酰胺吡啶脲作为血管内皮生长因子（VEGF）受体激酶抑制剂
-
Application No.: US11265517Application Date: 2005-11-03
-
Publication No.: US07902229B2Publication Date: 2011-03-08
- Inventor: Rolf Bohlmann , Martin Haberey , Andreas Huth , Stuart Ince , Martin Krueger , Karl-Heinz Thierauch , Holger Hess-Stumpp , Andreas Reichel
- Applicant: Rolf Bohlmann , Martin Haberey , Andreas Huth , Stuart Ince , Martin Krueger , Karl-Heinz Thierauch , Holger Hess-Stumpp , Andreas Reichel
- Applicant Address: DE Berlin
- Assignee: Bayer Schering Pharma AG
- Current Assignee: Bayer Schering Pharma AG
- Current Assignee Address: DE Berlin
- Agency: Millen, White, Zelano & Branigan, P.C.
- Priority: EP04090419 20041103
- Main IPC: A61K31/4439
- IPC: A61K31/4439 ; C07D401/12
Abstract:
The invention relates to novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.
Public/Granted literature
Information query
IPC分类:
